The Catalyst

Most Recent Posts

02.04.14 | By Josie Martin

Today, on World Cancer Day, we celebrate the remarkable progress that’s been made in the fight against a devastating disease that has touched all of us.

01.31.14 | By Mit Spears

 The Washington Legal Foundation recently convened an enlightening expert roundtable discussion about the impact of late 2012's decision in U.S. vs. Caronia. 

01.31.14 | By Preet Bilinski

What does working in a lab have in common with flying an airplane? A great deal according to the next researcher highlighted in our “I am Research, Progress, Hope” series, Dowdy Jackson, head of the Antibody Drug Conjugate (ADC) Biology group at Agensys, an affiliate of Astellas.

Johnson & Johnson logo
01.30.14 | By Mark Grayson

As of January 1, researchers are now able to submit proposals to receive access to patient level data, protocols, and clinical study reports for new medicines approved in the U.S and EU after January 1, 2014.  The biopharmaceutical sector’s commitment to data sharing provides new avenues for the scientific community and patients to benefit from clinical research, while maintaining patient privacy, the integrity of national regulators, and incentives for companies to make long-term investments in biomedical research.
 

01.30.14 | By Mark Grayson

Dr. Robert Freeman, Professor of Pharmacy Administration (health services research) in the Department of Pharmacy Practice & Administration at the University of Maryland Eastern Shore School of Pharmacy, comments on the recently released paper from University College London School of Pharmacy on patient’s needs and intellectual property in middle income countries.

01.30.14 | By Jay Taylor

In his State of the Union, President Obama said, "A nation that goes all-in on innovation today will own the global economy tomorrow." We couldn't agree more.

01.29.14 | By Preet Bilinski

Today’s featured scientist comes from Agensys, a subsidiary of Astellas, where she is working on developing a treatment or cure for different types of cancers.

01.28.14

The great inventor and businessman Henry Ford once said, “Whether you think you can, or think you can’t – you’re right."

01.28.14

When looking at an issue as important and complex as health care costs in the U.S., it’s critical that full facts, not select data, lead the discussion. Drew Armstrong’s recent article about a Hepatitis C medicine paints an incomplete picture of our health care system and further propels inaccurate information about prescription medicines.

01.28.14 | By Kristin Van Goor

When considering the benefits and risks of medicines, patients provide a unique perspective of unparalleled value.  A deep understanding of the patient perspective on benefits and risks throughout the drug development process has the potential to significantly advance the biopharmaceutical industry’s efforts to bring to patients new medicines that extend and improve the quality of their lives.  

01.28.14 | By Stephanie Fischer

Before the holidays, PhRMA’s General Counsel Mit Spears wrote a post in The Catalyst about the need for a new regulatory paradigm to govern how the biopharmaceutical industry communicates with healthcare professionals about the medicines that our companies research and develop.

01.27.14 | By Stephanie Fischer

Dr. Richard Moscicki, Deputy Center Director for Science Operations at the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), noted in his remarks at the FDA public workshop on Complex Issues in Developing Drug and Biological Products for Rare Diseases held earlier this month that more than a third of the novel drugs approved in CY13 treat rare disease.

01.24.14 | By Kaelan Hollon

Nelson Mandela once said, “Education is the most powerful weapon which you can use to change the world.” This statement couldn't be more accurate.

01.24.14 | By Preet Bilinski

This week at the STEM Saves Lives forum, we were fortunate enough to hear from the first woman of color to go into space. Now, we hear from a woman who considered taking a similar path, but instead decided to pursue a career in biopharmaceutical research.

Pages